Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESECT: Re-resection in T1HG Bladder Cancer
NCT03266900Phase 1Terminated
- Sponsor
- University Health Network
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in bladder urothelial carcinoma (2 arms), sponsored by University Health Network. Primary endpoint: Progression Free Survival at 5 years. Started Nov 2017; status: terminated.
02
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03266900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266900.